Results 51 to 60 of about 9,029 (175)

Amylin analogues as a novel perspective in anti‐obesity therapy

open access: yesBritish Journal of Pharmacology, EarlyView.
Abstract Public health systems face a major challenge because of the worldwide obesity epidemic. The number of obese individuals has increased dramatically and, even in Switzerland which may be considered a relatively “lean” country, the numbers are alarmingly high and have reached almost 50% of the adult population.
Thomas A. Lutz
wiley   +1 more source

A Small Potassium Current in AgRP/NPY Neurons Regulates Feeding Behavior and Energy Metabolism

open access: yesCell Reports, 2016
Neurons that co-express agouti-related peptide (AgRP) and neuropeptide Y (NPY) are indispensable for normal feeding behavior. Firing activities of AgRP/NPY neurons are dynamically regulated by energy status and coordinate appropriate feeding behavior to ...
Yanlin He   +12 more
doaj   +1 more source

Evidence That Agouti-Related Peptide May Directly Regulate Kisspeptin Neurons in Male Sheep

open access: yesMetabolites, 2021
Agouti-related peptide (AgRP) neurons, which relay information from peripheral metabolic signals, may constitute a key central regulator of reproduction.
Christina M. Merkley   +3 more
doaj   +1 more source

Gut microbiota as a novel therapeutic target for eating disorders and obesity

open access: yesBritish Journal of Pharmacology, EarlyView.
The graphical abstract highlights the bidirectional interaction between the gut microbiota and central homeostatic and hedonic mechanisms regulating food intake, which contributes to overweight and obesity. It also illustrates emerging microbiota‐based biomarkers and therapeutic strategies (including prebiotics, probiotics, postbiotics, synbiotics and ...
Solveiga Samulėnaitė   +5 more
wiley   +1 more source

Reducing hypothalamic AGRP by RNA interference increases metabolic rate and decreases body weight without influencing food intake

open access: yesBMC Neuroscience, 2002
Background Several lines of evidence strongly suggest that agouti-related peptide (AGRP) plays a key role in the regulation of metabolic function but ablation of the AGRP gene has no apparent effect on metabolic function.
Mastaitis Jason W   +4 more
doaj   +1 more source

Therapeutic access points: The roles of circumventricular organs in drug delivery and metabolic regulation

open access: yesBritish Journal of Pharmacology, EarlyView.
The current obesity drug landscape, dominated by GLP‐1 receptor agonists and emerging multi‐agonist therapies, has reinforced that long‐term weight loss is achieved in large part through central mechanisms that suppress appetite and reshape energy balance.
Ines Martinez‐Corral   +3 more
wiley   +1 more source

A rare mutation in AgRP, +79G>A, affects promoter activity [PDF]

open access: yesEuropean Journal of Clinical Nutrition, 2006
The agouti-related protein is a powerful orexigenic peptide. A rare mutation, +79G>A, was identified in its minimal promoter in two white carriers. Comparison of the 45-year-old male proband, who was also a carrier of the common Ala67Thr polymorphism, with an age- and weight-matching wild-type population showed marginal differences for resting ...
Sozen, M. A.   +5 more
openaire   +3 more sources

Glucocorticoids and HPA axis regulation in the stress–obesity connection: A comprehensive overview of biological, physiological and behavioural dimensions

open access: yesClinical Obesity, Volume 15, Issue 2, April 2025.
Summary Chronic stress, characterized by increased long‐term exposure to the glucocorticoid hormone cortisol, is increasingly linked to obesity development. Still, various knowledge gaps persist, including on underlying pathophysiological mechanisms. The aim of the current review is to provide the latest insights on the connection between stress and ...
Robin Lengton   +4 more
wiley   +1 more source

Early Weight Regain After GLP‐1 Receptor Agonist Discontinuation: Mechanisms and Implications for Treatment De‐Escalation Strategies

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) have transformed the pharmacological management of obesity, producing substantial and sustained weight loss during active treatment. However, discontinuation of therapy is frequently followed by significant weight regain, raising important questions regarding the durability of treatment ...
M. A. Damhof   +2 more
wiley   +1 more source

Innovations in Obesity Treatment: Beyond Adipose Tissue Dysfunction

open access: yesObesity Reviews, EarlyView.
Obesity drives chronic inflammation, insulin resistance, type 2 diabetes, and cancer development through adipocyte dysfunction. Addressing this multisystemic disorder requires integrated strategies beyond diet and exercise, such as thermogenesis activation via menthol or capsinoids and appetite control through GLP‐1/GIP agonists and neuromodulation to ...
Jesica Martínez‐Godfrey   +7 more
wiley   +1 more source

Home - About - Disclaimer - Privacy